Welcome to the iCAD Investors Page

​Welcome to the iCAD Investors PageiCAD, Inc. is an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer. The core business delivers innovative cancer detection and radiation therapy solutions and services that enable clinicians to find and treat cancers earlier, while enhancing patient care. Comprehensive iCAD technology platforms include advanced hardware and software as well as management services designed to support cancer detection and radiation therapy (eBx) treatments.

The company's common stock is listed on the NASDAQ Stock Market under the symbol "ICAD."

From the Newsroom

​

May 18, 2023
iCAD’s Breast AI Suite Wins U.S. General Services Administration’s AI Healthcare Challenge Award

May 15, 2023
iCAD Reports Financial Results for First Quarter Ended March 31, 2023

May 11, 2023
New Long-Term Real-World Research Confirms Xoft Skin eBx is as Safe and Effective as Mohs Surgery

May 3, 2023
iCAD Showcases Breast AI Suite at Society of Breast Imaging Symposium, World’s Largest Breast Imaging Conference

May 01, 2023
iCAD to Report First Quarter 2023 Financial Results on May 15, 2023

Quick Links

• Corporate Profile

• Events & Webcasts

• Financial News/Events

• Leadership

• Reports & SEC Files

• Stock Quote

• Corporate Governance

Resources

• Customer Testimonials

• Educational Webinars

Investor Relations

iCAD Investor Relations
ir@icadmed.com

Media Inquiries

iCAD, Inc.
603.882.5200
pr@icadmed.com

​Recycle - iCAD is committed to corporate sustainability and to making a difference for our environment.RoHS 2011 - iCAD is committed to corporate sustainability and to making a difference for our environment.China E - iCAD is committed to corporate sustainability and to making a difference for our environment.

iCAD is committed to corporate sustainability and to making a difference for our environment.

Recent Events and Webcasts

May 15, 2023
Webcast Icon4:30 pm ET
iCAD to Report First Quarter 2023 Financial Results on May 15, 2023

March 28, 2023
Webcast Icon4:30 pm ET
iCAD Previews Fourth Quarter Financial Results

November 10, 2022
Webcast Icon4:30 pm ET
iCAD to Report Third Quarter 2022 Financial Results on November 10, 2022

August 10, 2022
Webcast Icon4:30 pm ET
iCAD to Report Second Quarter 2022 Financial Results on August 10, 2022

May 17, 2022
Webcast Icon11:30 am ET
iCAD to Present at the Spring Into Action – Best Ideas Virtual Investor Conference

© iCAD Inc.  All rights reserved.  iCAD, the iCAD logo, PowerLook, ProFound AI, ProFound, Xoft, the Xoft logo, Axxent, Electronic Brachytherapy System and eBx are registered trademarks of iCAD, Inc. Reproduction of any of the material contained herein in any format or media without the express written permission of iCAD, Inc. is prohibited.

Facebook icon Twitter icon LinkedIn icon

​Welcome to the iCAD Investors PageiCAD, Inc. is an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer. The core business delivers innovative cancer detection and radiation therapy solutions and services that enable clinicians to find and treat cancers earlier, while enhancing patient care. Comprehensive iCAD technology platforms include advanced hardware and software as well as management services designed to support cancer detection and radiation therapy (eBx) treatments.

Welcome to the iCAD Investors Page